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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193S182a median of 1.18/uL (range 0.20/uL-2.54/uL) and the ANC
a median of 158/uL (range 0-1168/uL); 36/65 (55%) patients
in DGD received no G-CSF (at physician's discretion) and
those who received the drug did so starting on day 14
(median) post-transplant (range ¼11d-18d). There was no
difference in the incidence or duration of  grade III muco-
sitis, weight gain, rash or engraftment syndrome between
DGD and CGD groups. However, as shown in Table 1 the CGD
group had signiﬁcantly faster engraftment, abbreviation of
neutropenia, diminished antibiotics use, and shorter hospi-
talization. These effects were independent of CD 34 cell dose.
Primarily because of abbreviated hospital stay, there was
a 17% cost beneﬁt to the use of CGD, supporting the overall
beneﬁt of this treatment regimen for patients with MM who
receive ASCT.Table 1
Characteristics CGD group DGD group P value
Neutrophil Engraftment (days) 12 (11-14) 15 (11-20) <0.0001
Duration of neutropenia 7 (5-9) 10 (6-16) <0.0001
(ANC <500)
Duration of severe neutropenia 6 (4-9) 8 (4-10) <0.0001
(ANC < 100) days
Duration of intravenous antibiotics 5 (3-20) 8 (3-15) 0.016
Duration of hospital stay 17 (14-24) 19 (16-28) <0.0001135
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The Autologous Hematopoietic Stem Cell Transplantation
(AHSCT) is a therapeutic method used in various immuno-
logical, hematological and genetic disorders, which uses
patient's own stem cells collected from peripheral blood
after their (the stem cells) mobilization by granulocyte
colony-stimulating factors (GCS-F), in order to restore the
damaged or defective bone marrow function. Oxidative
stress and antioxidant depletion have been described during
the stages involved in AHSCT. Glutathione peroxidase is an
enzyme responsible for detoxiﬁcation of organic and inor-
ganic peroxides, which participates of enzymatic cellular
antioxidant defense. The aim of the study was to evaluate the
levels of glutathione peroxidase in various stages involving
AHSCT in patients undergoing autologous hematopoietic
stem cell transplantation. Glutathione peroxidase was
determined using the Glutathione Peroxidase Ransel kit
(Randox). We measured glutathione peroxidase levels of
eight patients at different times pre-and post-AHSCT: before
Conditioning Regimen (CR), 24 hours after chemotherapy, 10
days (D +10) and 20 days (D +20) after transplantation. There
was a statistically signiﬁcant difference in levels of gluta-
thione peroxidase after CR comparing to other times, sug-
gesting an increase in oxidative stress after chemotherapy.
According to previous studies, oxidative stress occurs acutely
after high-dose chemotherapy for AHSCT and is apparently
related to late hematological recovery. Thus, it can be sug-
gested the use of glutathione peroxidase levels, and otheroxidative stress parameters as toxicity and grafting markers
after AHSCT.136
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Introduction: Peripheral blood progenitor cell (PBPC)
mobilization with intermediate-dose cyclophosphamide (3-
4 gm/m2) (ID-CY) and G-CSF when compared to low-dose CY
(1-2 gm/m2)-based strategies, has been shown to have
a favorable risk/beneﬁt proﬁle in multiple myeloma (MM)
patients (pts) receiving novel induction therapies. However
the relative efﬁcacy of ID-CY as compared to plerixafor (P) in
PBPC mobilization in MM pts is not known. Herein we
report outcomes of ID-CY/G-CSFmobilization compared to P/
G-CSF mobilization in MM pts treated with novel
inductionregimens.
Methods: This multicenter outcomes study includes 84 pts
who underwent a planned, single autograft within 1-year
of starting induction therapy with novel chemotherapy
agents (thalidomide, lenalidomide, bortezomib). Consecu-
tive pts undergoing mobilization with ID-CY/G-CSF (3-4
gm/m2) (n¼55) at one institution were compared against
consecutive pts receiving plerixafor/G-CSF (0.24 mg/kg)
(n¼29) at a different transplant center. In order to assess
efﬁciency of PBPC mobilization, we evaluated peak
peripheral blood (PB) CD34+ cell counts, CD34+ cell yield
on day1 of collection, total CD34+ cell collection, and total
number of apheresis sessions. Mobilization failure was
deﬁned as failure to collect 2 x106 cells/kg body weight.
All pts with normal renal function received uniform
conditioning with Mel200 (MEL140 if serum creatinine
was 2 mg/dl).
Results: At baseline, the ID-CY and P cohorts were well
balanced. No difference was observed in the use of lenali-
domide (p¼0.3). Compared to P, ID-CY use was associated
with higher median peak PB CD34+ cell count (63/ml vs. 160/
ml, P¼ .01), CD34+ yield on day 1 of collection (6.5 x106/kg vs.
11.7 x106/kg, P ¼ .004), and total CD34+ cell yield (10.5 x106/
kg vs. 24.9 x106/kg, P ¼ .001). Median numbers of apheresis
sessions were 2.2 in each group (p¼0.9). No mobilization
failures were seen in either group. Therewas no difference in
the proportion of pts collecting 5x106/kg CD34+ cells in
either group (93% vs. 96%, P ¼ .6), but more pts in ID-CY
cohort collected 10x106/kg CD34+ cells (55% vs. 78%, P ¼
.02). Neutrophil engraftment was signiﬁcantly faster (9.9
